Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TQB2450 and Anlotinib in High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma
NCT07602101Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart and anlotinib in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Primary endpoint: Rate of Successful Nephron-Sparing Surgery. Planned start May 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07602101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602101.